Spots Global Cancer Trial Database for plerixafor
Every month we try and update this database with for plerixafor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor | NCT01403896 | Malignant Lymph... | Plerixafor (Moz... Plerixafor + G-... | 18 Years - 30 Years | Nova Scotia Health Authority | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | NCT01301963 | Refractory Mult... | plerixafor filgrastim | 19 Years - | Case Comprehensive Cancer Center | |
| Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization | NCT01037517 | Multiple Myelom... Lymphoma | Plerixafor Observation: No... | 18 Years - | CancerCare Manitoba | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | NCT00396383 | Multiple Myelom... | plerixafor | 18 Years - 75 Years | Sanofi | |
| Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | NCT00741325 | Non-Hodgkin's L... Autologous Tran... | granulocyte col... plerixafor Placebo | - | Sanofi | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | NCT04552743 | Multiple Myelom... | MGTA-145 Plerixafor | 18 Years - 70 Years | Stanford University | |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | NCT01696461 | Related Donors ... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | Plerixafor | 18 Years - 65 Years | Center for International Blood and Marrow Transplant Research | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) | NCT01065129 | Myelodysplastic... | G-CSF Plerixafor Azacitidine | 18 Years - | Washington University School of Medicine | |
| Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | NCT00741780 | Multiple Myelom... Autologous Tran... | Placebo plerixafor granulocyte col... | - | Sanofi | |
| Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT01074060 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim cyclophosphamid... autologous hema... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | NCT01160354 | Acute Myelogeno... | Plerixafor Clofarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) | NCT01065129 | Myelodysplastic... | G-CSF Plerixafor Azacitidine | 18 Years - | Washington University School of Medicine | |
| Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | NCT01042717 | Multiple Myelom... Non-Hodgkins Ly... | Plerixafor | 18 Years - 75 Years | Shi, Patricia, M.D. | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma | NCT01547806 | Plasma Cell Mye... Multiple Myelom... | Filgrastim Plerixafor Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) | NCT01065129 | Myelodysplastic... | G-CSF Plerixafor Azacitidine | 18 Years - | Washington University School of Medicine | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | NCT01301963 | Refractory Mult... | plerixafor filgrastim | 19 Years - | Case Comprehensive Cancer Center | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. | NCT02006225 | Autologous Stem... | Plerixafor | - 30 Years | Tel-Aviv Sourasky Medical Center | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | NCT04552743 | Multiple Myelom... | MGTA-145 Plerixafor | 18 Years - 70 Years | Stanford University | |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | NCT06141304 | Relapsed Adult ... Relapsed Adult ... | Plerixafor | 14 Years - 60 Years | The First Hospital of Jilin University | |
| Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | NCT00906945 | Leukemia, Myelo... | G-CSF Plerixafor Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | NCT06207799 | Multiple Myelom... Post-transplant... Pre-transplant ... | Elranatamab Lenalidomide Plerixafor Melphalan Busulfan G-CSF Stem cell trans... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV | NCT05470491 | HIV Hematologic Mal... | RIC GVHD prophylaxi... allo HCT Plerixafor Maraviroc | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00990054 | Acute Myeloid L... | Plerixafor | 18 Years - 70 Years | Sanofi | |
| Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | NCT00741325 | Non-Hodgkin's L... Autologous Tran... | granulocyte col... plerixafor Placebo | - | Sanofi | |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | NCT01160354 | Acute Myelogeno... | Plerixafor Clofarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | NCT01339572 | Non-Hodgkin's L... Multiple Myelom... | Plerixafor Filgrastim | 18 Years - | University of Florida | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | NCT00741780 | Multiple Myelom... Autologous Tran... | Placebo plerixafor granulocyte col... | - | Sanofi | |
| Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | NCT01977677 | Adult Ependymob... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Medullobl... Adult Mixed Gli... Adult Oligodend... Adult Pineoblas... Adult Supratent... | radiation thera... temozolomide plerixafor laboratory biom... pharmacological... | 18 Years - 75 Years | Stanford University | |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies | NCT04762875 | Related Donors ... Healthy Donors Acute Myelogeno... Acute Lymphobla... Myelodysplastic... | MGTA-145 Plerixafor | 18 Years - 65 Years | Ensoma | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | NCT00669669 | Glioblastoma Gliosarcoma | 3-Dimensional C... Autologous Hema... Carmustine Filgrastim In Vitro-Treate... Intensity-Modul... Laboratory Biom... O6-Benzylguanin... Plerixafor Proton Beam Rad... Temozolomide | 18 Years - | Fred Hutchinson Cancer Center | |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | NCT03506802 | HLA-A*0201 Posi... NY-ESO-1 Positi... Recurrent Plasm... Refractory Plas... | 18F-FHBG Aldesleukin Cellular Therap... Computed Tomogr... Filgrastim Laboratory Biom... Lenalidomide Leukapheresis Melphalan Plerixafor Positron Emissi... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients | NCT03406091 | Multiple Myelom... | Plerixafor | 18 Years - | Fondazione EMN Italy Onlus | |
| Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | NCT02098109 | Multiple Myelom... Lymphoma, Non-H... | XM02 Filgrastim Filgrastim Apheresis Plerixafor Stem Cell Trans... | 18 Years - | Washington University School of Medicine | |
| IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) | NCT01027923 | Leukemia, Myelo... | Plerixafor Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. | NCT00720603 | Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... | Plerixafor | 18 Years - | Sanofi | |
| Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells | NCT01097057 | Non-Hodgkin Lym... | Carboplatin Etoposide Filgrastim Ifosfamide Leukapheresis Plerixafor Rituximab | 18 Years - | Fred Hutchinson Cancer Center | |
| Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. | NCT02006225 | Autologous Stem... | Plerixafor | - 30 Years | Tel-Aviv Sourasky Medical Center | |
| O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | NCT00669669 | Glioblastoma Gliosarcoma | 3-Dimensional C... Autologous Hema... Carmustine Filgrastim In Vitro-Treate... Intensity-Modul... Laboratory Biom... O6-Benzylguanin... Plerixafor Proton Beam Rad... Temozolomide | 18 Years - | Fred Hutchinson Cancer Center | |
| To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | NCT03277209 | Pancreas Cancer | Plerixafor | 18 Years - | Weill Medical College of Cornell University | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies | NCT04762875 | Related Donors ... Healthy Donors Acute Myelogeno... Acute Lymphobla... Myelodysplastic... | MGTA-145 Plerixafor | 18 Years - 65 Years | Ensoma | |
| Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT02570542 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | leukapheresis Plerixafor carmustine, eto... Autologous Stem... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells | NCT01753453 | Multiple Myelom... | Plerixafor Granulocyte-col... | 18 Years - | Sanofi | |
| Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT01074060 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim cyclophosphamid... autologous hema... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | NCT01042717 | Multiple Myelom... Non-Hodgkins Ly... | Plerixafor | 18 Years - 75 Years | Shi, Patricia, M.D. | |
| Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor | NCT01403896 | Malignant Lymph... | Plerixafor (Moz... Plerixafor + G-... | 18 Years - 30 Years | Nova Scotia Health Authority | |
| T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | NCT01621477 | Acute Lymphobla... Acute Myelocyti... Chronic Myelocy... Juvenile Myelom... Myelodysplastic... Hodgkin or Non-... Sarcoma, Myeloi... | clofarabine cytarabine busulfan Plerixafor cyclophosphamid... antithymocyte g... stem cells Tacrolimus mycophenolate m... | - 21 Years | St. Jude Children's Research Hospital | |
| Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection | NCT01095757 | Myeloma Lymphoma | Plerixafor | 18 Years - 70 Years | Emory University | |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | NCT06141304 | Relapsed Adult ... Relapsed Adult ... | Plerixafor | 14 Years - 60 Years | The First Hospital of Jilin University | |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer | NCT03240861 | HLA-A*0201 Posi... Locally Advance... NY-ESO-1 Positi... Unresectable Ma... Sarcoma | 18F-FHBG Aldesleukin Busulfan Cellular Therap... Computed Tomogr... Filgrastim Fludarabine Leukapheresis Plerixafor Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | NCT02343666 | Human Immunodef... Stage I Adult H... Stage I Adult N... Stage II Adult ... Stage II Adult ... Stage III Adult... Stage III Adult... Stage IV Adult ... Stage IV Adult ... | C46/CCR5/P140K ... Carmustine Filgrastim Laboratory Biom... O6-Benzylguanin... Plerixafor | 18 Years - 66 Years | Fred Hutchinson Cancer Center | |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma | NCT01547806 | Plasma Cell Mye... Multiple Myelom... | Filgrastim Plerixafor Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers | NCT02682953 | Bone Marrow Tra... Hematopoietic S... Multiple Myelom... Lymphoma | Neupogen Hyperbaric oxyg... Plerixafor | 21 Years - | University of Maryland, Baltimore | |
| Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | NCT01318317 | Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Non-H... | Autologous Hema... Filgrastim Genetically Eng... Laboratory Biom... Peripheral Bloo... Plerixafor Rituximab | 18 Years - | City of Hope Medical Center | |
| Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | NCT01352650 | Acute Myeloid L... | plerixafor decitabine | 60 Years - | Weill Medical College of Cornell University | |
| Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | NCT03746080 | Glioblastoma Glioblastoma Wi... Gliosarcoma Malignant Gliom... Oligodendroglia... | Plerixafor Temozolomide Whole-Brain Rad... Radiation Thera... | 18 Years - 75 Years | Stanford University | |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | NCT05088356 | Allogeneic Hema... Advanced Hemato... Acute Leukemia Chronic Myeloge... Myelodysplastic... Myeloproliferat... | Purified regula... Fludarabine Melphalan CliniMACS CD34 ... Tacrolimus Cyclophosphamid... Plerixafor Filgrastim gran... Thiotepa Mycophenolate M... Ruxolitinib | 18 Years - 75 Years | Stanford University | |
| Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | NCT01352650 | Acute Myeloid L... | plerixafor decitabine | 60 Years - | Weill Medical College of Cornell University | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia | NCT00512252 | Leukemia, Myelo... | AMD3100 Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | NCT01977677 | Adult Ependymob... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Medullobl... Adult Mixed Gli... Adult Oligodend... Adult Pineoblas... Adult Supratent... | radiation thera... temozolomide plerixafor laboratory biom... pharmacological... | 18 Years - 75 Years | Stanford University | |
| Non-interventional Study on Salvage Auto in Relapsed Myeloma | NCT02439476 | Relapsed Multip... | 18 Years - 75 Years | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | ||
| Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | NCT00733824 | Lymphoma, Non-H... Hodgkin Disease | AMD3100 G-CSF Apheresis | 18 Years - 75 Years | Washington University School of Medicine | |
| Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation | NCT01610999 | Chronic Lymphoc... Lymphoma Multiple Myelom... | Plerixafor | 18 Years - | Tufts Medical Center | |
| Mozobil for Autologous Stem Cell Mobilization | NCT01164345 | Non-Hodgkin's L... Hodgkin's Lymph... Stem Cell Mobil... Autologous Stem... | Plerixafor | 18 Years - 75 Years | Sheba Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
